Urinary Tract Infection Market Research Report - Global Forecast till 2027

尿路感染症市場:薬物クラス別の情報(キノロン(シプロフロキサシン、エノキサシン、ノルフロキサシン、オフロキサシン、ペフロキサシン、フレロキサシン)、β-ラクタムおよびセファロスポリン(アモキシシリン-クラブラン酸、セフジニル、セファクロル、セフポドキシム-プロキシチル)、アミノグリコシド、ペニシリン、アゾール)、アプリケーション(尿道炎、膀胱炎、腎盂腎炎)、病原体(大腸菌、ブドウ球菌、肺炎クレブシエラ、プロテウス・ミラビリス、エンテロコッカス・フェカリス)、エンドユーザー(病院、クリニック、自己投与)および地域(アメリカ大陸、ヨーロッパ、アジア太平洋、その他の地域)-予測 2027年まで

ID: MRFR/MED/4680-CR | February 2021 | Region: Global | 164 Pages         

1 EXECUTIVE SUMMARY

1.1 MARKET ATTRACTIVENESS ANALYSIS 18

2 MARKET INTRODUCTION

2.1 DEFINITION 19

2.2 SCOPE OF THE STUDY 19

2.3 RESEARCH OBJECTIVE 19

2.4 MARKET STRUCTURE 19

2.5 ASSUMPTIONS & LIMITATIONS 20

3 RESEARCH METHODOLOGY

3.1 DATA MINING 21

3.2 SECONDARY RESEARCH 22

3.3 PRIMARY RESEARCH 23

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 25

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26

3.6.1 BOTTOM-UP APPROACH 27

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 28

3.8 VALIDATION 28

4 MARKET DYNAMICS

4.1 OVERVIEW 29

4.2 DRIVERS 30

4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30

4.2.2 LAUNCH OF COMBINATION DRUGS 30

4.3 RESTRAINTS 31

4.3.1 COMPLEX REGULATORY REQUIREMENTS 31

4.4 OPPORTUNITIES 32

4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 33

5.1.1 R&D AND DESIGNING 34

5.1.2 MANUFACTURING 34

5.1.3 DISTRIBUTION & SALES 34

5.1.4 POST-SALES SERVICES 34

5.2 PORTER’S FIVE FORCES MODEL 35

5.2.1 BARGAINING POWER OF SUPPLIERS 36

5.2.2 BARGAINING POWER OF BUYERS 36

5.2.3 THREAT OF NEW ENTRANTS 36

5.2.4 THREAT OF SUBSTITUTES 36

5.2.5 RIVALRY 36

5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37

5.3.1 OVERVIEW 37

5.3.2 IMPACT ON SUPPLY CHAIN 37

5.3.3 IMPACT ON PRODUCTION 38

6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS

6.1 OVERVIEW 40

6.2 QUINOLONES 42

6.3 Β-LACTAM & CEPHALOSPORINS 43

6.4 AMINOGLYCOSIDES 44

6.5 PENICILLIN 44

6.6 AZOLES 45

7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION

7.1 OVERVIEW 46

7.2 URETHRITIS 47

7.3 CYSTITIS 48

7.4 PYELONEPHRITIS 48

8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN

8.1 OVERVIEW 49

8.2 ESCHERICHIA COLI 50

8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51

8.4 KLEBSIELLA PNEUMONIAE 51

8.5 PROTEUS MIRABILIS 52

8.6 ENTEROCOCCUS FAECALIS 52

9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER

9.1 OVERVIEW 53

9.2 HOSPITALS 54

9.3 CLINICS 54

9.4 SELF-ADMINISTERED 55

10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION

10.1 OVERVIEW 56

10.2 AMERICAS 58

10.2.1 NORTH AMERICA 61

10.2.1.1 US 64

10.2.1.2 CANADA 67

10.2.2 LATIN AMERICA 70

10.3 EUROPE 73

10.3.1 WESTERN EUROPE 76

10.3.1.1 GERMANY 80

10.3.1.2 FRANCE 83

10.3.1.3 UK 86

10.3.1.4 ITALY 89

10.3.1.5 SPAIN 92

10.3.1.6 REST OF WESTERN EUROPE 95

10.3.2 EASTERN EUROPE 98

10.4 ASIA-PACIFIC 101

10.4.1 CHINA 105

10.4.2 INDIA 108

10.4.3 JAPAN 111

10.4.4 AUSTRALIA 114

10.4.5 SOUTH KOREA 117

10.4.6 REST OF ASIA-PACIFIC 120

10.5 MIDDLE EAST & AFRICA 123

10.5.1 MIDDLE EAST 126

10.5.2 AFRICA 129

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 132

11.2 COMPETITIVE BENCHMARKING 133

11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2020 134

11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134

11.4.1 PRODUCT APPROVALS AND LAUNCHES 134

11.4.2 ACQUISITIONS 134

11.5 FINANCIAL MATRIX 135

12 COMPANY PROFILES

12.1 PFIZER INC. 136

12.1.1 COMPANY OVERVIEW 136

12.1.2 FINANCIAL OVERVIEW 137

12.1.3 PRODUCTS/SERVICES OFFERED 138

12.1.4 KEY DEVELOPMENTS 138

12.1.5 SWOT ANALYSIS 138

12.1.6 KEY STRATEGIES 139

12.2 NOVO NORDISK A/S 140

12.2.1 COMPANY OVERVIEW 140

12.2.2 FINANCIAL OVERVIEW 140

12.2.3 PRODUCTS/SERVICES OFFERED 141

12.2.4 KEY DEVELOPMENTS 141

12.2.5 SWOT ANALYSIS 141

12.2.6 KEY STRATEGIES 141

12.3 NOVARTIS AG 142

12.3.1 COMPANY OVERVIEW 142

12.3.2 FINANCIAL OVERVIEW 142

12.3.3 PRODUCTS/SERVICES OFFERED 143

12.3.4 KEY DEVELOPMENTS 143

12.3.5 SWOT ANALYSIS 143

12.3.6 KEY STRATEGIES 144

12.4 MERCK & CO., INC. 145

12.4.1 COMPANY OVERVIEW 145

12.4.2 FINANCIAL OVERVIEW 145

12.4.3 PRODUCTS/SERVICES OFFERED 146

12.4.4 KEY DEVELOPMENTS 146

12.4.5 SWOT ANALYSIS 146

12.4.6 KEY STRATEGIES 146

12.5 ELI LILY AND COMPANY 147

12.5.1 COMPANY OVERVIEW 147

12.5.2 FINANCIAL OVERVIEW 147

12.5.3 PRODUCTS/SERVICES OFFERED 148

12.5.4 KEY DEVELOPMENTS 148

12.5.5 SWOT ANALYSIS 148

12.5.6 KEY STRATEGIES 148

12.6 ALLERGAN 149

12.6.1 COMPANY OVERVIEW 149

12.6.2 FINANCIAL OVERVIEW 149

12.6.3 PRODUCTS/SERVICES OFFERED 150

12.6.4 KEY DEVELOPMENTS 150

12.6.5 SWOT ANALYSIS 150

12.6.6 KEY STRATEGIES 150

12.7 CIPLA INC. 151

12.7.1 COMPANY OVERVIEW 151

12.7.2 FINANCIAL OVERVIEW 151

12.7.3 PRODUCTS/SERVICES OFFERED 151

12.7.4 KEY DEVELOPMENTS 151

12.7.5 SWOT ANALYSIS 152

12.7.6 KEY STRATEGIES 152

12.8 TEVA PHARMACEUTICALS 153

12.8.1 COMPANY OVERVIEW 153

12.8.2 FINANCIAL OVERVIEW 153

12.8.3 PRODUCTS/SERVICES OFFERED 154

12.8.4 KEY DEVELOPMENTS 154

12.8.5 SWOT ANALYSIS 154

12.8.6 KEY STRATEGIES 155

12.9 GLAXOSMITHKLINE PLC 156

12.9.1 COMPANY OVERVIEW 156

12.9.2 FINANCIAL OVERVIEW 156

12.9.3 PRODUCTS/SERVICES OFFERED 157

12.9.4 KEY DEVELOPMENTS 157

12.9.5 SWOT ANALYSIS 157

12.9.6 KEY STRATEGIES 157

12.10 BAYER AG 158

12.10.1 COMPANY OVERVIEW 158

12.10.2 COMPANY VALUE 158

12.10.3 FINANCIAL OVERVIEW 159

12.10.4 PRODUCTS/SERVICES OFFERED 159

12.10.5 KEY DEVELOPMENTS 159

12.10.6 SWOT ANALYSIS 160

12.10.7 KEY STRATEGIES 160

13 APPENDIX

13.1 REFERENCES 161

13.2 RELATED REPORTS 161

14 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

TABLE 3 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 41

TABLE 4 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2020-2027 (USD MILLION) 42

TABLE 5 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 42

TABLE 6 GLOBAL URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY REGION, 2020-2027 (USD MILLION) 43

TABLE 7 GLOBAL URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 43

TABLE 8 GLOBAL URINARY TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 9 GLOBAL URINARY TRACT INFECTION MARKET, FOR PENICILLIN, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 10 GLOBAL URINARY TRACT INFECTION MARKET, FOR AZOLES, BY REGION, 2020-2027 (USD MILLION) 45

TABLE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 47

TABLE 12 GLOBAL URINARY TRACT INFECTION MARKET, FOR URETHRITIS, BY REGION, 2020-2027 (USD MILLION) 47

TABLE 13 GLOBAL URINARY TRACT INFECTION MARKET, FOR CYSTITIS, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 14 GLOBAL URINARY TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 15 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 50

TABLE 16 GLOBAL URINARY TRACT INFECTION MARKET, FOR ESCHERICHIA COLI, BY REGION, 2020-2027 (USD MILLION) 50

TABLE 17 GLOBAL URINARY TRACT INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2020-2027 (USD MILLION) 51

TABLE 18 GLOBAL URINARY TRACT INFECTION MARKET, FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2020-2027 (USD MILLION) 51

TABLE 19 GLOBAL URINARY TRACT INFECTION MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2020-2027 (USD MILLION) 52

TABLE 20 GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION, 2020-2027 (USD MILLION) 52

TABLE 21 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 54

TABLE 22 GLOBAL URINARY TRACT INFECTION MARKET, FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 54

TABLE 23 GLOBAL URINARY TRACT INFECTION MARKET, FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 54

TABLE 24 GLOBAL URINARY TRACT INFECTION MARKET, FOR SELF-ADMINISTERED, BY REGION, 2020-2027 (USD MILLION) 55

TABLE 25 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 57

TABLE 26 AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 58

TABLE 27 AMERICAS: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 58

TABLE 28 AMERICAS: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 59

TABLE 29 AMERICAS: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 59

TABLE 30 AMERICAS: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60

TABLE 31 AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 60

TABLE 32 AMERICAS: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 60

TABLE 33 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 61

TABLE 34 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 61

TABLE 35 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 62

TABLE 36 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 62

TABLE 37 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 63

TABLE 38 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 63

TABLE 39 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 63

TABLE 40 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 64

TABLE 41 US: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 64

TABLE 42 US: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 65

TABLE 43 US: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 65

TABLE 44 US: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 66

TABLE 45 US: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 66

TABLE 46 CANADA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 67

TABLE 47 CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 67

TABLE 48 CANADA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 49 CANADA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68

TABLE 50 CANADA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 69

TABLE 51 CANADA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 69

TABLE 52 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 70

TABLE 53 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 70

TABLE 54 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 71

TABLE 55 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72

TABLE 56 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 72

TABLE 57 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 72

TABLE 58 EUROPE: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 73

TABLE 59 EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 73

TABLE 60 EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 74

TABLE 61 EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 74

TABLE 62 EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 75

TABLE 63 EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 75

TABLE 64 EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 75

TABLE 65 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 76

TABLE 66 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 77

TABLE 67 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 77

TABLE 68 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 78

TABLE 69 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78

TABLE 70 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 79

TABLE 71 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 79

TABLE 72 GERMANY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 80

TABLE 73 GERMANY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 74 GERMANY: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 81

TABLE 75 GERMANY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81

TABLE 76 GERMANY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 82

TABLE 77 GERMANY: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 82

TABLE 78 FRANCE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 83

TABLE 79 FRANCE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 80 FRANCE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 84

TABLE 81 FRANCE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84

TABLE 82 FRANCE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 85

TABLE 83 FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 85

TABLE 84 UK: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 86

TABLE 85 UK: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 86

TABLE 86 UK: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 87

TABLE 87 UK: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 87

TABLE 88 UK: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 88

TABLE 89 UK: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 88

TABLE 90 ITALY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 89

TABLE 91 ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 92 ITALY: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 90

TABLE 93 ITALY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90

TABLE 94 ITALY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 91

TABLE 95 ITALY: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 91

TABLE 96 SPAIN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 92

TABLE 97 SPAIN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 98 SPAIN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 93

TABLE 99 SPAIN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 93

TABLE 100 SPAIN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 94

TABLE 101 SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 94

TABLE 102 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 95

TABLE 103 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 104 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 105 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 96

TABLE 106 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 97

TABLE 107 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 97

TABLE 108 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 98

TABLE 109 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 98

TABLE 110 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 99

TABLE 111 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 99

TABLE 112 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 100

TABLE 113 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 100

TABLE 114 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 101

TABLE 115 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 102

TABLE 116 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 102

TABLE 117 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 103

TABLE 118 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 103

TABLE 119 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 104

TABLE 120 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 104

TABLE 121 CHINA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 105

TABLE 122 CHINA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 105

TABLE 123 CHINA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 106

TABLE 124 CHINA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 106

TABLE 125 CHINA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 107

TABLE 126 CHINA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 107

TABLE 127 INDIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 108

TABLE 128 INDIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 108

TABLE 129 INDIA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 109

TABLE 130 INDIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 109

TABLE 131 INDIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 110

TABLE 132 INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 110

TABLE 133 JAPAN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 111

TABLE 134 JAPAN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 111

TABLE 135 JAPAN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 112

TABLE 136 JAPAN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 112

TABLE 137 JAPAN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 113

TABLE 138 JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 113

TABLE 139 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 114

TABLE 140 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 141 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 115

TABLE 142 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 115

TABLE 143 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 116

TABLE 144 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 116

TABLE 145 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 117

TABLE 146 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 117

TABLE 147 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 118

TABLE 148 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 118

TABLE 149 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 119

TABLE 150 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 119

TABLE 151 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 120

TABLE 152 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 153 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 121

TABLE 154 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121

TABLE 155 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 122

TABLE 156 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 122

TABLE 157 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 123

TABLE 158 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 123

TABLE 159 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 160 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 161 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 125

TABLE 162 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 125

TABLE 163 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 125

TABLE 164 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 126

TABLE 165 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 126

TABLE 166 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 127

TABLE 167 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 127

TABLE 168 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 128

TABLE 169 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 128

TABLE 170 AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 129

TABLE 171 AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 129

TABLE 172 AFRICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 130

TABLE 173 AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130

TABLE 174 AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 131

TABLE 175 AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 131

TABLE 176 MAJOR MANUFACTURERS RANKING, 2020 134

TABLE 177 PRODUCT APPROVALS AND LAUNCHES 134

TABLE 178 ACQUISITIONS 134

TABLE 179 PFIZER INC.: PRODUCTS/SERVICES OFFERED 138

TABLE 180 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED 141

TABLE 181 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 143

TABLE 182 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 146

TABLE 183 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148

TABLE 184 ALLERGAN: PRODUCTS/SERVICES OFFERED 150

TABLE 185 CIPLA INC.: PRODUCTS/SERVICES OFFERED 151

TABLE 186 CIPLA INC.: KEY DEVELOPMENTS 151

TABLE 187 TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154

TABLE 188 TEVA PHARMACEUTICALS: KEY DEVELOPMENTS 154

TABLE 189 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 157

TABLE 190 BAYER AG: COMPANY VALUE 158

TABLE 191 BAYER AG.: PRODUCTS/SERVICES OFFERED 159

15 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 17

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS, BY REGION, 2020 18

FIGURE 3 GLOBAL URINARY TRACT INFECTION MARKET: STRUCTURE 19

FIGURE 4 BOTTOM-UP AND TOP-DOWN APPROACHES 26

FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL URINARY TRACT INFECTION (UTI) MARKET 29

FIGURE 6 DRIVER IMPACT ANALYSIS 31

FIGURE 7 RESTRAINT IMPACT ANALYSIS 32

FIGURE 8 VALUE CHAIN: GLOBAL URINARY TRACT INFECTION MARKET 33

FIGURE 9 PORTER’S FIVE FORCES ANALYSIS: GLOBAL URINARY TRACT INFECTION MARKET 35

FIGURE 10 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020 AND 2027 (USD MILLION) 41

FIGURE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 46

FIGURE 12 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020 AND 2027 (USD MILLION) 49

FIGURE 13 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 53

FIGURE 14 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 57

FIGURE 15 AMERICAS: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 58

FIGURE 16 NORTH AMERICA: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 61

FIGURE 17 EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 73

FIGURE 18 WESTERN EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 76

FIGURE 19 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 101

FIGURE 20 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 123

FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS 133

FIGURE 22 SALES & OPERATING INCOME MARGIN, 2020 135

FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE, 2020 135

FIGURE 24 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 137

FIGURE 25 PFIZER INC.: SWOT ANALYSIS 138

FIGURE 26 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 140

FIGURE 27 NOVO NORDISK A/S: SWOT ANALYSIS 141

FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 142

FIGURE 29 NOVARTIS AG: SWOT ANALYSIS 143

FIGURE 30 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 145

FIGURE 31 MERCK & CO., INC.: SWOT ANALYSIS 146

FIGURE 32 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 147

FIGURE 33 ELI LILY AND COMPANY: SWOT ANALYSIS 148

FIGURE 34 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT 149

FIGURE 35 ALLERGAN: SWOT ANALYSIS 150

FIGURE 36 CIPLA INC.: SWOT ANALYSIS 152

FIGURE 37 TEVA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 153

FIGURE 38 TEVA PHARMACEUTICALS: SWOT ANALYSIS 154

FIGURE 39 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 156

FIGURE 40 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 157

FIGURE 41 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT 159

FIGURE 42 BAYER AG.: SWOT ANALYSIS 160

尿路感染症市場

尿路感染症市場はCAGR 3.5%で上昇し、2027年の世界予測期間の終わりまでに113億米ドル相当の市場評価に達すると予想されています。

セグメンテーション

By Drug Class Quinolones Beta & Cephalosporins Aminoglycosides Penicillin Azoles
アプリケーション別 Urethritis Cystitis Pyelonephritis
By Pathogen Escherichia Coli Staphylococcus Saprophyticus Klebsiella Pneumoniae Proteus Mirabilis Enterococcus Faecalis
By End User Hospitals Clinics Self Administered

キープレーヤー

  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Novo Nordisk A/S
  • GlaxoSmithKline plc
  • Bayer AG
  • Novartis Ag
  • Cipla Inc.
  • Merck & Co. Inc.
  • Eli Lily Company
  • Allergan

運転手

  • Superiority for treating patients who are suffering from a kidney infection
Speak to Analyst Request a Free Sample

尿路感染症市場の概要


糖尿病を患っており、さらに泌尿器科の健康問題にかかっている人は、非常に密接な関係があります。糖尿病はさらに健康上の問題を引き起こし、膀胱の問題と並んでUTIに感染するリスクを高めます。また、糖尿病は、泌尿器科の問題や状態などの問題の状態を悪化させる可能性があります。これは、これらが個人の血流、神経の機能に影響を与え、身体によって実行される感覚機能にも影響を与えることが知られているためです。世界各地に住む巨大な人口は、糖尿病の健康状態の影響を受けています。また、これは腎臓結石のような他の一般的に発生する問題をさらに引き起こし、また、日を追うごとに報告されるUTI症例数の増加をもたらしています。同様の病気に苦しんでいる患者は、世界規模で治療と薬を要求しているため、2027年の世界的な予測期間の終わりまでに尿路感染症市場に顕著な上昇をもたらす可能性があります。


これらの傾向、感染の増加、および薬物と治療の需要により、市場レポートは市場規模にとって有望で増加する将来を反映しています。尿路感染症市場はCAGR 3.5%で上昇し、2027年の世界予測期間の終わりまでに113億米ドル相当の市場評価に達すると予想されています。


COVID19 分析


新しいコロナウイルスがその視野を広げ、さまざまな産業、市場の垂直市場、企業、国に参入しているため、研究者はさまざまな感染症の亜種を治療するためのより多くの知識とワクチン開発を進めています。状況の逆境のために、人々は一般的な医療構造の能力に疑問を抱いており、したがって、設備が整い、更新された、技術関連のインフラストラクチャを要求しています。また、パンデミックの蔓延は、企業や企業の生産部門と製造部門にとって非常に悪いものでした。彼らは、尿路感染症業界の需要と生産レベルに応える能力がなく、能力がないため、閉鎖を余儀なくされています。一方、ヘルスケアサービスは増加しています。


しかし、医療従事者はコロナウイルス病にかかった患者の治療に雇用されており、糖尿病やUTIなどの他の問題に苦しんでいる患者は苦労しています。そのため、政府は、高度な技術に基づくインフラストラクチャの開発における投資決定に関して、主要な市場関係者と協力しており、質的かつ効率的な方法で要求に応えています。


尿路感染症市場の動向


ドライバー


尿路感染症市場の主要なプレーヤーは、世界中の視聴者のニーズに合ったより多くの薬剤を組み合わせて発売するために、研究開発部門に投資しています。例えば、FDAは、腎臓感染症に罹患している患者を治療するための組み合わせとして優位性を持っています。したがって、これらは、予測期間中の予想どおりに尿路感染症市場が成長するのに役立ちます。


拘束


現在、抗菌薬の設計と試験のプロセスは、精巧で複雑な手順です。また、これらの手続き中に倫理的および科学的アプローチがないと、評価期間中の予想どおりに市場が成長するのを抑制する可能性があります。


テクノロジー分析


尿路感染症市場は、治療薬のカテゴリーに属する抗体の臨床試験を選択しています。試行デザイン、解釈、精巧な分析などの手順を実行した後に提示されたアプローチと結果を十分に尊重します。試験を承認するには、有益で倫理的な使用の強化を目的とした簡単な方法で薬剤を設計する方がよい。また、市場のプレーヤーは、同様の要件に応えるために、科学的なアプローチと開発手順に従う可能性があります。したがって、尿路感染症市場には、2027年に終了する有望な世界的な予測期間があります。


研究目標



  • 市場の概要を把握し、パンデミックが市場運営に与える影響を調査し、さらに、予測期間中に市場が成長するために利用できる推進力、機会、制約などのダイナミクスについて話し合う

  • の主要地域における市場運営とセグメントのパフォーマンスを調査および分析する 世界。これらは収益の洞察を与え、投資家が投資とマーケティングの決定を下すのにも役立ちます

  • 2027年に終了する予測期間中の最近の動向を通じて、主要な市場プレーヤーと彼らが着手した成長戦略についてのアイデアを持つことにより、市場に蔓延している競争の程度を分析すること


尿路感染症の市場シェア、タイプ別、2019(%)
Urinary Tract Infections Market


ソース:MRFR 分析


米国尿路感染症市場セグメントの概要


尿路感染症市場の成長について議論するには、世界市場の収益サイクルについての考えを持つことが不可欠です。市場は、事業と収益の可能性を理解するのに役立つセグメントに分かれています。これは、採用される投資決定と市場戦略に違いをもたらします。グローバル市場は、以下のヘッドに基づいて分割されています


薬物クラス


尿路感染症は、キノロン、アミノグリコシド、アゾールなどの薬物、ペニシリン、セファロスポリンなどの薬を扱っています。キノロンは、フレロキサシンとともに、エノキサシン、ペフロキサシン、ノルフロキサシンにさらに分割されています。2019年、これは市場で最も成長率の高いサブセグメントでした。


アプリケーション


尿路感染症の適用セグメントには、膀胱炎、腎盂腎炎、尿道炎などが含まれます。尿道炎は2019年に最大の市場シェアを経験しました。


病原体


このセグメントには、大腸菌、クレブシエラ肺炎、プロテウスミラビリスなどが含まれます。


市場エンドユーザー


病院、ヘルスケアセンター、クリニックは、自己管理型のものと並んで、尿路感染症市場の市場エンドユーザーです。


2019年の世界の尿路感染症市場シェア、地域別(%)


Urinary Tract Infections Market


ソース:MRFR 分析


地域分析


ラテンアメリカに加えて、米国やカナダなどの国で構成される北米市場。北米市場は、尿路感染症市場の世界的な成長に役立つ治療製品と診断に向けた革新と技術の進歩への投資の急増を期待しています。米国は、この地域の人口の間でUTIと腎臓の問題が蔓延しているため、需要によりますますグローバル市場シェアを獲得しています。収入の面で2番目に大きい地域的成長は、ヨーロッパ諸国によって経験される可能性が高い。市場に関連する経済的負担はヨーロッパで増加しています。しかし、在職期間中の最も速い成長は、意識が高まり、人々がそれに関連する教育を受けているため、APAC尿路感染症市場によって経験される可能性があります。


競争環境


市場の主要な市場プレーヤーの間で競争力のあるグラフを描き、実施された最近の動向を通じて収益の可能性を評価するには、機能性尿路感染症市場のプレーヤーについてのアイデアを持つことが重要です。それらは次のとおりです。



  • ファイザー社

  • テバファーマシューティカルズ

  • ノボノルディスク A/S

  • グラクソ・スミスクライン

  • バイエル社

  • ノバルティス社

  • Cipla Inc.

  • メルク & Co., Inc.

  • イーライリリー

  • 会社、アラガン


最近の動向



  • 国際糖尿病連盟は、糖尿病患者に関するデータと統計を発表しました。公開データによると、約46



    Report Scope:
    Report Attribute/Metric Details
      Market Size   USD 11.3 Billion
      CAGR   3.5% (2020 - 2027)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   By Drug Class, Application, End-User, Region
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Pfizer Inc., Teva Pharmaceuticals, Novo Nordisk A/S, GlaxoSmithKline plc, Bayer AG, Novartis Ag, Cipla Inc., Merck & Co., Inc., Eli Lily, Company, Allergan
      Key Market Opportunities   Key market players are investing in the research and development departments for combining and launching more drugs
      Key Market Drivers   superiority for treating patients who are suffering from a kidney infection


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The urinary tract infection (UTI) market would grow up to USD9.89 billion by 2023.

    The urinary tract infection (UTI) market would grow with a 3.6% CAGR during the forecast period of 2018 to 2023.

    North America would display strong market positioning among all the urinary tract infection (UTI) market players.

    The US would trigger growth for the North American urinary tract infection (UTI) market.

    The Asia Pacific would be the fastest in terms of growth among all the urinary tract infection (UTI) market players.